Title | Germline SAMD9L truncation variants trigger global translational repression. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Allenspach, EJ, Soveg, F, Finn, LS, So, L, Gorman, JA, Rosen, ABI, Skoda-Smith, S, Wheeler, MM, Barrow, KA, Rich, LM, Debley, JS, Bamshad, MJ, Nickerson, DA, Savan, R, Torgerson, TR, Rawlings, DJ |
Journal | J Exp Med |
Volume | 218 |
Issue | 5 |
Date Published | 2021 May 03 |
ISSN | 1540-9538 |
Abstract | SAMD9L is an interferon-induced tumor suppressor implicated in a spectrum of multisystem disorders, including risk for myeloid malignancies and immune deficiency. We identified a heterozygous de novo frameshift variant in SAMD9L in an infant with B cell aplasia and clinical autoinflammatory features who died from respiratory failure with chronic rhinovirus infection. Autopsy demonstrated absent bone marrow and peripheral B cells as well as selective loss of Langerhans and Purkinje cells. The frameshift variant led to expression of a truncated protein with interferon treatment. This protein exhibited a gain-of-function phenotype, resulting in interference in global protein synthesis via inhibition of translational elongation. Using a mutational scan, we identified a region within SAMD9L where stop-gain variants trigger a similar translational arrest. SAMD9L variants that globally suppress translation had no effect or increased mRNA transcription. The complex-reported phenotype likely reflects lineage-dominant sensitivities to this translation block. Taken together, our findings indicate that interferon-triggered SAMD9L gain-of-function variants globally suppress translation. |
DOI | 10.1084/jem.20201195 |
Alternate Journal | J Exp Med |
PubMed ID | 33724365 |
PubMed Central ID | PMC7970252 |
Grant List | UM1 HG006493 / HG / NHGRI NIH HHS / United States |